Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms

被引:452
作者
Rasmusson, I
Ringdén, O
Sundberg, B
Le Blanc, K
机构
[1] Huddinge Univ Hosp, Div Clin Immunol, Karolinska Inst, SE-14186 Stockholm, Sweden
[2] Huddinge Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden
关键词
marrow stromal cells; mixed lymphocyte cultures; prostaglandin;
D O I
10.1016/j.yexcr.2004.12.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human mesenchymal stern cells (MSCs) have immuno-modulatory properties. They inhibit T-cell proliferation to mitogens and alloantigens in vitro and prolong skin graft survival in vivo. We found that MSCs inhibited the proliferation of peripheral blood lymphocytes (PBLs) to phorbol myristate acetate (PMA), suggesting that NISCs exert an inhibitory effect downstream of the receptor level. We analyzed cytokine profiles of PBLs co-cultured with MSCs. MSCs increased interleukin (IL)-2 and soluble IL-2 receptor in mixed lymphocyte cultures (MLCs), while IL-2 and IL-2R decreased in phytohemagglutinin (PHA)-stimulated PBL cultures. MSCs inhibited IL-2 induced proliferation, without absorbing IL-2. IL-10 levels increased in MLCs co-cultured with 10% MSCs, while the levels were not affected in PHA cultures. In MLCs inhibited by MSCs, antibodies against IL-10 further suppressed proliferation but had no effect in PHA cultures. Addition of indomethacin, an inhibitor of prostaglandin-synthesis, restored part of the inhibition by MSCs in PHA cultures. However, indomethacin did not affect MSC-induced inhibition in MLCs. To conclude, our data indicate that MSC-induced suppression is a complex mechanism affecting IL-2 and IL-10 signaling and may function differently, depending on T-cell stimuli. Prostaglandins are important in the inhibition by MSCs when the T cells were activated by PHA, but not alloantigens. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 37 条
  • [1] AGGARWAL S, 2004, BLOOD, V19
  • [2] DUAL FUNCTION OF RECOMBINANT HUMAN CD58 - INHIBITION OF T-CELL ADHESION AND ACTIVATION VIA THE CD2 PATHWAY
    ALBERTWOLF, M
    MEUER, SC
    WALLICH, R
    [J]. INTERNATIONAL IMMUNOLOGY, 1991, 3 (12) : 1335 - 1347
  • [3] Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation
    Almeida-Porada, G
    Porada, CD
    Tran, N
    Zanjani, ED
    [J]. BLOOD, 2000, 95 (11) : 3620 - 3627
  • [4] Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice
    Angelopoulou, M
    Novelli, E
    Grove, JE
    Rinder, HM
    Civin, C
    Cheng, LZ
    Krause, DS
    [J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (05) : 413 - 420
  • [5] Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo
    Bartholomew, A
    Sturgeon, C
    Siatskas, M
    Ferrer, K
    McIntosh, K
    Patil, S
    Hardy, W
    Devine, S
    Ucker, D
    Deans, R
    Moseley, A
    Hoffman, R
    [J]. EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) : 42 - 48
  • [6] BEYTH S, 2004, BLOOD, V28
  • [7] Cytokine secretion in mixed lymphocyte culture: a prognostic indicator of renal allograft rejection in addition to HLA mismatching
    Cartwright, NH
    Demaine, AG
    Hurlock, NJ
    McGonigle, RJ
    Rowe, PA
    Shaw, JF
    Szydlo, RM
    Kaminski, ER
    [J]. TRANSPLANT IMMUNOLOGY, 2000, 8 (02) : 109 - 114
  • [8] DANZER SG, 1994, TRANSPLANTATION, V57, P1638
  • [9] RAPAMYCIN INHIBITS THE IN-VITRO RELEASE OF SOLUBLE INTERLEUKIN-2 RECEPTOR BY ACTIVATED PERIPHERAL-BLOOD MONONUCLEAR-CELLS (PBMC) INDEPENDENTLY OF THE MODE OF ACTIVATION
    DEGIANNIS, D
    HORNUNG, N
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1995, 17 (07): : 593 - 596
  • [10] MIXED LYMPHOCYTE REACTION-INDUCED RELEASE OF SOLUBLE IL-2 RECEPTOR
    DEGIANNIS, D
    CZARNECKI, M
    HORNUNG, N
    RASKOVA, J
    RASKA, K
    [J]. TRANSPLANTATION, 1991, 51 (02) : 518 - 523